How Photobiomodulation Works

Photobiomodulation is not heat and it is not ablation. LM™ LLLT (PBM) delivers non-ionising, monochromatic light that acts on cellular activity rather than on tissue structure. Understanding the mechanism explains why a single modality can help across several different drivers of disease, and why it appears in more than one place in the TFOS DEWS III treatment matrix.

The mitochondrial effect

The principal target is the mitochondrion, the cell's energy plant. Absorbed light promotes the release of adenosine triphosphate (ATP), the molecule cells use for energy, and modulates hypoxia-inducible factors (HIF-α) that govern how cells respond to stress and low oxygen. The downstream result is cellular rejuvenation: cells under metabolic strain are nudged back toward healthy function.

Vasodilation and nitric oxide

Light exposure increases nitric-oxide signalling, which relaxes blood vessels and improves local perfusion. In the periocular tissues and the retina, better blood flow supports tissue recovery; in the back of the eye in particular, enhanced choriocapillaris perfusion is one of the signals reported in early dry AMD studies (Viggiano et al., 2025, Eye).

Reduced inflammatory signalling

Photobiomodulation dampens inflammatory signalling. On the ocular surface and at the eyelid, where inflammation is a recurring driver of dry eye and meibomian gland dysfunction, calming that signalling translates into a more stable tear film, better gland function and less surface damage.

In the posterior segment

In the retina, the same biology takes on additional relevance. Photobiomodulation has been associated with restored mitochondrial function and ATP production in photoreceptors, and yellow-wavelength light has been described as inhibiting VEGF expression, the signal that drives abnormal blood-vessel growth. These mechanisms are the rationale for investigating LM™ LLLT in dry AMD.

Why the mechanism matters clinically

Because the effect is biological and acts on shared cellular pathways, one course of treatment can address several drivers a patient carries at once, a compromised lipid layer, gland dysfunction, an aqueous shortfall and surface staining, rather than targeting only one. That breadth is precisely why DEWS III recognises it across all three driver groups (TFOS DEWS III, 2025, American Journal of Ophthalmology). For the colours involved, see wavelengths explained.

Not all solutions and indications are cleared in all countries and for all cohorts. Every piece of information ought to be considered as fact-based evidence deriving from publicly available literature, for the sole purpose of scientific exchange.